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EDITORIAL
A blast from the mast?
The accumulation of chronic inflammatory cells in the
cortical interstitial space plays a pivotal role in the forma-
tion of tubulointerstitial fibrosis (TIF) in progressive
chronic renal diseases. Inflammatory cells secrete fibrotic
mediators, which incite matrix-producing cells to deposit
extracellular matrix proteins in the interstitium. Contem-
porary research has concentrated on delineating the func-
tions of T lymphocytes and monocytes/macrophages in
this pathologic process [1]. Until recently, the contribu-
tion of the mast cell to TIF has largely been overlooked
[2–3]. In this issue of Kidney International, Jones et al
[4] provide the first evidence to suggest that mast cell
accumulation could, in part, mediate TIF in the remnant
kidney rat model of progressive non–immune-mediated
chronic renal disease.
To begin generating a tangible hypothesis that mast
cells are one of the key cellular participants in TIF, it is
pertinent to appreciate their basic biology. Mast cells are
bone marrow–derived blood-borne precursor cells that
mysteriously enter the mucosal surfaces and connective
tissue compartments of organs [5–6]. Here, they differen-
tiate, proliferate, and evolve into a group of durable senti-
nel cells, trained to monitor the local microenvironment for
noxious stimuli for weeks to months. Mast cells exhibit
considerable tissue-specific functional heterogeneity, and
this is a consequence of the paracrine influence of the
resident organ. In humans there are at least three different
phenotypes (positive for tryptase only, positive for chymase
only, and positive for tryptase and chymase), whose physio-
logic roles remain to be defined. While the habitual role
of the mast cell was once thought to be restricted to
mediating type I allergic reactions via immunoglubulin E
(IgE)-dependent mechanisms, they are now recognized
to be important cellular transducers of not only innate
immunity, but also chronic inflammation, angiogenesis,
tissue remodeling, and fibrosis. These multifunctional capa-
bilities are evidenced by the possession of cell-surface re-
ceptors for the Fc portion of IgE, cytokines/growth fac-
tors [c-kit, the ligand for stem-cell factor (SCF), which
induces mast cell migration, differentiation, and degran-
ulation], cell adhesion molecules (ICAM-1, CD44), and
microbes (Toll-like receptors). Upon receptor engage-
ment, mast cells transform into aggressive and highly versa-
tile effector cells. Depending on the inciting stimuli, mast
cells extrude from their secretory granules a plethora of
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preformed (most notably histamine, but also heparin,
neutral proteases—tryptase, chymase, acid hydrolases,
cathepsin G, carboxypeptidase) and formed inflamma-
tory substances, including lipid mediators [prostaglandin
D2, leukotriene C4, thromboxane A2, polyclonal antibody
(PAF)], cytokines [tumor necrosis factor- (TNF-), in-
terleukin (IL)-1, IL-3–6, IL-13, granulocyte macrophage
colony stimulating factor (GM-CSF), interferon-gamma
(IFN-)], chemokines [macrophage inflammatory pro-
tein-1 (MIP-1), trichloroacetic acid-3 (TCA-3), mono-
cyte chemoattractactant protein-1 (MCP-1), endothelin],
growth factors [platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), transforming growth
factor-1 (TGF-1)], matrix metalloproteinases, and ma-
trix proteins. Mast cells secrete active TGF-1 by simul-
taneously releasing latent TGF-1 together with the acti-
vating enzyme, chymase 1. In coculture in vitro studies
mast cell products caused the activation and proliferation
of fibroblasts [7].
In the normal kidney, mast cells are constitutively
expressed in small numbers [3]. However, in a variety
of human renal diseases, the number of mast cells in the
renal interstitium is increased. These include glomerular
diseases (IgA nephropathy, membranous nephropathy,
crescentic glomerulonephritis, diabetic nephropathy),
tubulointerstitial diseases (chronic pyelonephritis, cyclo-
sporin nephrotoxicity), and allograft rejection. In IgA ne-
phropathy and chronic allograft disease, interstitial mast
cell number is correlated with renal function and TIF
[3]. In animal models, interstitial mast cell accumulation
is increased in rats fed a magnesium-deficient diet and
in IL-9 transgenic mice, whereas mast cells do not appear
to be present in serum sickness nephritis rat, Masugi ne-
phritis, or rat Thy-1 nephritis [3].
In the remnant kidney rat model, Jones et al [5] found
that renal injury correlated positively with interstitial
mast cell accumulation (as determined by toluidine blue
staining and chymase/tryptase immunohistochemistry).
Although the tubular cell protein expression of the mast
cell chemokine, SCF, was increased, it is notable that
whole kidney mRNA levels of SCF and the other mast
cell chemokines (IL-8, TGF-1) did not correlate pre-
cisely with mast cell numbers. Mast cells being profibrotic
in this model was suggested by the following: (1) mast
cells expressed TGF-1; (2) mast cells were localized to
regions of tubular injury and peritubular fibrosis; and (3)
renoprotection with angiotensin blockade was associated
with a reduction in interstitial mast cell accumulation.
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The protective effect of angiotensin blockade may hold
particular relevance because chymase is a potent pro-
ducer of angiotensin II.
However, the data by Jones et al [4] provide only indi-
rect proof of the importance of mast cell activation in
TIF, and further studies are needed to strengthen the
hypothesis, as well as elucidate the relative importance
of mast cells in comparison to other inflammatory cells.
Potential experimental strategies for the future include
the induction of renal disease models in mast cell–deficient
mice (such as W/WV, c-kit mutant; Sl/Sld, c-kit ligand
mutant) combined with reconstitution studies [2, 8–9];
the in vivo administration of pharmacologic inhibitors
of chymase and mast-cell stabilizing agents, particularly
in established disease models; and co-culture in vitro
studies of mast cells and their paracrine interactions with
tubular epithelial and renal fibroblast cells. Bearing in
mind the limitations of these latter approaches, such
studies have been performed in non-renal disease mod-
els. These data suggest that mast cells either have a
major, partial, or insignificant role in non-renal fibrosis,
depending on the disease model examined. In addition,
other basic questions about mast cell biology in renal
disease remain unanswered; for example, is mast cell
accumulation dependent on local proliferation and dif-
ferentiation, rather than recruitment? What regulates
mast cell survival, and do they undergo apoptosis, when
there is resolution of injury?
More than 100 years ago, Erlich, who was the first to
recognize the mast cell in tissues, named them ‘Mastzel-
len’ to signify the chunky and well-nourished appearance
of these cells with huge cytoplasmic granules [3]. This
simple histologic observation perhaps predicts the enor-
mous paracrine potential of the mast cell and its postu-
lated role as an important cellular mediator of fibrosis. If
mast cells do indeed turn out to be one of the pathologic
players in TIF, then this will provide an additional thera-
peutic approach for established human chronic renal dis-
eases, possibly using the new generation of mast-cell
stabilizing drugs which are currently in development [10].
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